Why is Quest Diagnostics stock surging today? By Investing.com
Quest Diagnostics (DGX) shares rose about 7.3% in pre-open trading after the company reported Q2 2026 adjusted EPS of $3.12 versus $2.82 expected, and revenue of $3.04B versus $2.97B. Quest lifted full-year guidance to $11.95B-$12.05B revenue and $11.05-$11.25 adjusted EPS. Jefferies raised its price target to $225 from $220.
How this was made
The 30-second read
Why it matters
Traders can treat this as a fresh fundamental reset for FY 2026 expectations, with the raised revenue and adjusted EPS ranges likely to influence valuation models and near-term positioning.
Market read
DGX is repricing on a same-day earnings and guidance catalyst, not on broader market direction.
What to watch
The article does not break out margin drivers, test volume trends, or payer mix, so follow-through may depend on whether the beat is durable beyond one quarter.
Background
The piece frames DGX’s move as a convergence of an earnings beat, raised full-year guidance, and a same-day analyst price-target hike.
Ticker impact
Quest Diagnostics reported Q2 2026 adjusted EPS of $3.12 vs $2.82 consensus and revenue of $3.04B vs $2.97B, driving a pre-open surge.
Bullish bias for the next session(s) as traders digest the raised FY revenue and adjusted EPS ranges.
The article cites same-day, before-market results with explicit upside guidance and an analyst price-target increase, which are direct catalysts for repricing.
Market effects
A strong diagnostics earnings print can support sentiment toward clinical lab operators and managed-care reimbursement expectations.
Primarily US large-cap sentiment, with the article noting S&P 500, Dow, and Nasdaq down while DGX rose.
Limited direct global spillover; impact is mostly within US healthcare diagnostics.
Counterpoint
The stock may be overextended after a large pre-market gap, and the guidance beat could already be partially priced by momentum traders.
Key entities
- companyQuest Diagnostics
Reported Q2 2026 adjusted EPS and revenue beats and lifted full-year 2026 guidance, prompting a pre-open rally.
- analyst_firmJefferies
Raised its price target on DGX to $225 from $220 while maintaining a Buy rating.
